Centogene N.V. (CNTG)

NASDAQ: CNTG · IEX Real-Time Price · USD
0.470
+0.020 (4.47%)
At close: Apr 22, 2024, 3:59 PM
0.489
+0.019 (4.02%)
After-hours: Apr 22, 2024, 4:00 PM EDT
4.47%
Market Cap 13.10M
Revenue (ttm) 55.72M
Net Income (ttm) -62.11M
Shares Out 27.87M
EPS (ttm) -1.54
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 434,319
Open 0.463
Previous Close 0.450
Day's Range 0.456 - 0.550
52-Week Range 0.431 - 2.520
Beta -0.81
Analysts Strong Buy
Price Target 1.50 (+219.08%)
Earnings Date Sep 7, 2023

About CNTG

Centogene N.V., together with its subsidiaries, engages in the research and development of products for human genetics in Europe, the Middle East, North America, Latin America, and the Asia Pacific. It provides data-driven answers to patients, physicians, and pharmaceutical companies for rare and neurodegenerative diseases. It operates through two segments: Pharmaceutical and Diagnostics. The company provides target and drug screening, clinical development, market access and expansion, as well as CENTOGENE Biodatabank licenses and insight repor... [Read more]

Sector Healthcare
IPO Date Nov 7, 2019
Employees 444
Stock Exchange NASDAQ
Ticker Symbol CNTG
Full Company Profile

Financial Performance

In 2022, Centogene's revenue was 47.47 million, an increase of 12.40% compared to the previous year's 42.23 million. Losses were -31.92 million, -30.31% less than in 2021.

Financial numbers in EUR Financial Statements

Analyst Forecast

According to one analyst, the rating for CNTG stock is "Strong Buy" and the 12-month stock price forecast is $1.5.

Price Target
$1.5
(219.08% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

CENTOGENE Receives Nasdaq Non-Compliance Notice

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, April 02, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG) (“Centogene”, “we”, or the “Company”), the essential life science partner for data-dr...

20 days ago - GlobeNewsWire

CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, March 19, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenera...

4 weeks ago - GlobeNewsWire

CENTOGENE Collaborates on Research Published in Science Showing Immunopathological Landscape of Human Pre-TCRα Deficiency

Complete Pre-TCRα Deficiency Found to be Very Rare, Partial Form More Common Than Expected Complete Pre-TCRα Deficiency Found to be Very Rare, Partial Form More Common Than Expected

7 weeks ago - GlobeNewsWire

CENTOGENE Explores Strategic Alternatives

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG) (the “Company”), the essential life science partner for data-driven answers in rare an...

7 weeks ago - GlobeNewsWire

CENTOGENE Announces Receipt of Nasdaq Notice of Delisting and Intention to Request a Hearing

Notice of Delisting Will Not Immediately Result in the Suspension or Delisting of the Company's Securities Notice of Delisting Will Not Immediately Result in the Suspension or Delisting of the Company...

7 weeks ago - GlobeNewsWire

CENTOGENE and the Laboratory of Human Genetics of Infectious Diseases at Institut Imagine Announce Rare Disease Research Collaboration

Aims to Leverage Diversified Data to Accelerate and De-Risk Drug Discovery and Clinical Development Aims to Leverage Diversified Data to Accelerate and De-Risk Drug Discovery and Clinical Development

3 months ago - GlobeNewsWire

CENTOGENE Receives French Research Tax Credit Accreditation

CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Centogene N.V.

3 months ago - GlobeNewsWire

CENTOGENE Announces Preliminary Full Year 2023 Revenue

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerat...

3 months ago - GlobeNewsWire

CENTOGENE Announces Voting Results of Extraordinary General Meeting

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerat...

4 months ago - GlobeNewsWire

CENTOGENE's Frontotemporal Dementia (FTD) Genetic Study, EFRONT, Reaches Initial Patient Enrollment Milestone

CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenera...

4 months ago - GlobeNewsWire

CENTOGENE and Lifera, a Public Investment Fund (PIF) Company, Complete Strategic Joint Venture Transaction

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerat...

5 months ago - GlobeNewsWire

CENTOGENE, University College London, and Global Team of Researchers Discover Gene Associated With New Neurodevelopmental Disease Linked to Early-Onset Dystonia and Parkinsonism

Collaborative research initiative leveraged CENTOGENE's Whole Exome Sequencing (WES) to reveal disease-causing gene called ACBD6 (Acyl-CoA Binding Domain Containing 6) Over seven years, a total of 45 ...

5 months ago - GlobeNewsWire

CENTOGENE Expands Multiomic Diagnostic Portfolio With Newly-Launched Transcriptomic Offering

Incorporating RNA sequencing provides better diagnostics to enable a more complete understanding of disease biology Incorporating RNA sequencing provides better diagnostics to enable a more complete u...

6 months ago - GlobeNewsWire

CENTOGENE to Present at H.C. Wainwright 25th Annual Global Investment Conference

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenera...

8 months ago - GlobeNewsWire

CENTOGENE Reports First Half 2023 Financial Results

Strong Revenues and Steady Growth in Both Diagnostics and Pharma Segments Drive Sustainable Financial Performance Strong Revenues and Steady Growth in Both Diagnostics and Pharma Segments Drive Sustai...

8 months ago - GlobeNewsWire

Centogene shares climb after study confirms biomarker for Gaucher disease

Shares of Centogene NV CNTG, +8.31% gained 7% premarket on Friday after the company announced data confirming the utility of its proprietary biomarker lyso-Gb1 in indicating the severity of Gaucher di...

8 months ago - Market Watch

CENTOGENE Announces Publication Establishing Lyso-Gb1 as a Predictive Biomarker for Gaucher Disease Patients

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Sept. 01, 2023 (GLOBE NEWSWIRE) -- CENTOGENE N.V. (Nasdaq: CNTG) (the “Company”), the essential life science partner for data-driven answers in rare a...

8 months ago - GlobeNewsWire

CENTOGENE Receives Nasdaq Non-Compliance Notification Regarding Minimum Market Value of Publicly Held Shares Deficiency

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG) (“we” or the “Company”), the essential life science partner for data-driven answers in...

8 months ago - GlobeNewsWire

CENTOGENE to Participate in Upcoming Conferences in August

CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenera...

9 months ago - GlobeNewsWire

CENTOGENE Regains Compliance With Nasdaq Listing Requirements

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, July 14, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG) (the “Company”), the essential life science partner for data-driven answers in rare an...

10 months ago - GlobeNewsWire

CENTOGENE Biodatabank Reveals Unique Genetic Variants in World's Largest Niemann-Pick Type C1 Disease Cohort

Results Published in European Journal of Human Genetics Demonstrate Unprecedented Insights to Accelerate Potential Treatment Options Results Published in European Journal of Human Genetics Demonstrate...

10 months ago - GlobeNewsWire

Lifera and CENTOGENE, Enter Strategic Collaboration - Forming Saudi Arabian Joint Venture to Increase Access to Leading Data-Driven Multiomic Testing

Joint Venture (JV) combines CENTOGENE's global leadership in multiomics with local insight of Lifera, a biopharmaceutical company wholly owned by the Public Investment Fund (PIF) based in Riyadh. JV f...

10 months ago - PRNewsWire

CENTOGENE Announces Approval of All Resolutions Tabled at 2023 Annual General Meeting

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 30, 2023 (GLOBE NEWSWIRE) -- CENTOGENE N.V. (Nasdaq: CNTG) (the “Company”), the essential life science partner for data-driven answers in rare an...

10 months ago - GlobeNewsWire

Centogene shares jump on joint venture with Lifera

Shares of Centogene NV CNTG, -2.20%, which specializes in genetic diagnostics for rare diseases, jumped 50% in premarket trading Tuesday after the company announced a joint venture with Lifera, a biop...

10 months ago - Market Watch

CENTOGENE and Lifera, a Biopharma Company Owned by the PIF, Enter Strategic Collaboration – Forming Saudi Arabian Joint Venture to Increase Access to Leading Data-Driven Multiomic Testing and Securing CENTOGENE $30 Million Investment

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN and RIYADH, Saudi Arabia, June 27, 2023 (GLOBE NEWSWIRE) -- CENTOGENE N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers i...

10 months ago - GlobeNewsWire